Biocon: Company Statement
Biocon (BIOCON) filed a disclosure titled "Company Statement". The company is valued at about ₹57,202 crore.
What happened
Biocon (BIOCON) filed a disclosure with the exchanges on 14 October 2026 at 08:25 AM titled "Company Statement".
Company snapshot
Biocon is a mid-cap company in the Healthcare sector, with a market value of about ₹57,202 crore.
The stock last traded at ₹351, against a 52-week range of ₹337.7–₹447.2 (21.5% below the high).
Before this filing the shares had moved −11.6% over the month and −20.8% over three months. Average daily turnover over the last 20 sessions was about ₹104 crore.
Promoters held 44.68% at the end of Q1 FY27. Foreign institutions owned 8.14% and domestic institutions 23.38%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 3,942 | 31.4 | 0.26 |
| Q2 FY26 | 4,296 | 84.5 | 0.66 |
| Q3 FY26 | 4,173 | 143.8 | 1.08 |
| Q4 FY26 | 4,517 | 125.9 | 0.79 |
| Q1 FY27 | 4,336 | 141.1 | 0.87 |
What history shows
This is not the company's first approval disclosure: BCEIE has 2 earlier filings of this kind on record since May 2026.
After those filings, the stock fell 1.5% on average the next trading day and was up 1.3% on average after five days (2 filings with price data).
Across 109 similar disclosures by other Healthcare companies, shares moved +0.6% on average the next day and +1.1% over five days; 53% of them rose the next day.
Market-wide, 1,502 approval filings with an impact score of 50 or more saw an average next-day move of +0.2%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 25 Sept 2026 | 'Company Statement'. | −3.1% | — |
| 18 Aug 2026 | Company Statement | +0.2% | +1.3% |
In the news
Recent coverage elsewhere (links open the original publisher):
- Biocon (NSEI:BIOCON) Stock Forecast & Analyst Predictions
- Biocon Share Price Near Low; Fundamentals Under Spotlight
- Biocon founder Kiran Mazumdar Shaw says India must shift pharma industry from generics to innovation-led g
- Natural Biocon (India) Says Arunkumar Dashrathbhai Prajapati Resigns As Managing Director
- Biocon tanks 10% on lower-than-expected December quarter results
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.